Stay updated on Margetuximab Pembrolizumab Combo in HER2(+) Gastric Cancer Clinical Trial
Sign up to get notified when there's something new on the Margetuximab Pembrolizumab Combo in HER2(+) Gastric Cancer Clinical Trial page.

Latest updates to the Margetuximab Pembrolizumab Combo in HER2(+) Gastric Cancer Clinical Trial page
- Check6 days agoNo Change Detected
- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedPublications section now notes that entries are automatically filled from PubMed, and the Revision label was updated from v3.2.0 to v3.3.2.SummaryDifference0.1%

- Check28 days agoChange DetectedRemoved the government funding status banner that warned of possible delays and directed users to opm.gov; core trial details remain unchanged.SummaryDifference0.3%

- Check42 days agoChange DetectedVisual and structural updates to the page are evident. Core study details, interventions, outcomes, and locations appear unchanged.SummaryDifference0.4%

- Check71 days agoChange Detected- Added a government funding notice and open status information for the NIH Clinical Center, and a link to operating status timelines. - Updated software revision to v3.2.0. - Removed the resource topic: Carcinoma of esophagus from Genetic and Rare Diseases Information Center.SummaryDifference3%

- Check78 days agoChange Detected- Updated version from v3.0.2 to v3.1.0. - No other content changes detected.SummaryDifference0.1%

- Check92 days agoChange DetectedVersion bumped from v3.0.1 to v3.0.2 and the 'Back to Top' link was removed. No substantive content changes detected.SummaryDifference0.2%

Stay in the know with updates to Margetuximab Pembrolizumab Combo in HER2(+) Gastric Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Margetuximab Pembrolizumab Combo in HER2(+) Gastric Cancer Clinical Trial page.